Cas No.: | 1134822-09-5 |
Chemical Name: | 3-Quinolinecarboxamide, N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-, benzenesulfonate (1:1) |
Synonyms: | VX-770 benzenesulfonate;VX 770 benzenesulfonate;VX770 benzenesulfonate |
SMILES: | O=S(=O)(O)C1C=CC=CC=1.CC(C)(C1C=C(C(C)(C)C)C(O)=CC=1NC(=O)C1C(=O)C2C=CC=CC=2NC=1)C |
Formula: | C30H34N2O6S |
M.Wt: | 550.6658 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Ivacaftor (VX-770, VX770) is a potent, orally bioavailable CFTR potentiator, increases G551D- and F508del CFTR-mediated Cl- secretion with EC50 of 100 nM; increases CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation in recombinant cells, increases the Po of G551D CFTR by 6-fold, the Po of F508del- and wild-type CFTR by 5-fold and 2-fold, respectively; also potentiates CFTR-mediated Cl− secretion in primary cultures of G551D/F508del HBE and F508del HBE; demonstrates potential for treatment of cystic fibrosis with certain mutations in CFTR gene (primarily the G551D mutation).FibrosisApproved |